Mach 1 Financial Group LLC Makes New $787,000 Investment in Medpace Holdings, Inc. $MEDP

Mach 1 Financial Group LLC acquired a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,401 shares of the company’s stock, valued at approximately $787,000.

Several other hedge funds have also modified their holdings of MEDP. NewEdge Advisors LLC boosted its stake in shares of Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after acquiring an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Medpace by 3.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after acquiring an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. boosted its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares in the last quarter. Sivia Capital Partners LLC purchased a new stake in shares of Medpace during the 2nd quarter worth about $296,000. Finally, M&T Bank Corp boosted its stake in shares of Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after acquiring an additional 31 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Trading Up 2.0%

Shares of Medpace stock opened at $430.10 on Friday. The firm has a market capitalization of $12.28 billion, a PE ratio of 27.03, a P/E/G ratio of 2.14 and a beta of 1.19. Medpace Holdings, Inc. has a twelve month low of $287.17 and a twelve month high of $628.92. The firm’s 50-day moving average price is $459.82 and its 200 day moving average price is $520.06.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm’s revenue for the quarter was up 26.5% on a year-over-year basis. During the same quarter last year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: A class action lawsuit has been filed against Medpace, with investors urged to seek lead-plaintiff status before a June 8, 2026 deadline.
• Negative Sentiment: Several law firms are publicizing claims that Medpace allegedly concealed or misrepresented cancellation-rate risks and growth expectations, increasing legal overhang.
• Negative Sentiment: The repeated investor alerts reference significant losses and a prior sharp stock decline, reinforcing concerns about potential damages and reputational impact.

Insiders Place Their Bets

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president owned 15,000 shares in the company, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 20.50% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the topic of several recent analyst reports. Royal Bank Of Canada lowered their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Truist Financial decreased their target price on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a research report on Friday, February 13th. Finally, Robert W. Baird decreased their target price on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $467.08.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.